top of page
Akamis Bio Immuno-Oncology.jpg

Harnessing the Power of Tumor Gene Therapy to Turn the Tide in the Battle Against Cancer

Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking tumor gene therapy platform to positively impact the lives of people living with cancer.

Our Lead Program

NG-350A (Phase 1b): An immuno-stimulatory tumor gene therapy driving intratumoral expression of a CD40 agonist monoclonal antibody.

Clinical Studies: FORTRESS, FORTIFY. 

Akamis Bio Virus
Akamis Bio 2 Transgene

To achieve our mission, we are developing a portfolio of Tumor-Specific Immuno-Gene (T-SIGn®) therapeutics which aim to enable a patient’s own immune system to recognize, attack, and clear their cancer. T-SIGn® therapeutics home specifically to solid tumors following intravenous delivery where they drive expression of therapeutic proteins to remodel the tumor microenvironment and trigger robust antitumor immune responses.

 

Our T-SIGn® therapeutics are a novel class of medicines with potential for use in the monotherapy setting, as well as in combination with other immuno-oncology agents, to deliver efficacy and offer new hope to people living with difficult-to-treat solid tumors.

Akamis Bio Clinical Trials Pipeline

A growing pipeline of T-SIGn® therapeutics aiming to enable a patient’s immune system to recognize, attack, and clear solid tumors .

T-SIGn® therapeutics are viral vector based, tumor gene therapies which are capable of homing specifically to primary and metastatic solid tumors following intravenous delivery. Once at the tumor site, T-SIGn® therapeutics can drive intratumoral expression of multiple immunologically active biomolecules and therapeutic proteins to remodel the tumor microenvironment and trigger robust antitumor immune responses.

Akamis Bio Full 1 to 1 Dilution
GettyImages-1297146235_edited.jpg

About Us

Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer.

bottom of page